Benchmark Reiterates Buy Rating for Biofrontera (NASDAQ:BFRI)

Biofrontera (NASDAQ:BFRI)‘s stock had its “buy” rating reissued by stock analysts at Benchmark in a report issued on Friday,Benzinga reports. They presently have a $7.00 price target on the stock.

Biofrontera Stock Performance

BFRI stock opened at $0.73 on Friday. The stock’s 50 day moving average price is $1.02 and its 200 day moving average price is $1.09. The firm has a market cap of $4.07 million, a P/E ratio of -0.32 and a beta of 0.50. Biofrontera has a 1 year low of $0.61 and a 1 year high of $4.04.

Biofrontera (NASDAQ:BFRI) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($1.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.19) by $0.07. The company had revenue of $7.84 million during the quarter, compared to analysts’ expectations of $9.02 million. Biofrontera had a negative return on equity of 652.37% and a negative net margin of 36.31%. On average, research analysts predict that Biofrontera will post -3.11 earnings per share for the current year.

Biofrontera Company Profile

Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.